MitoQndomized into three study arms comparing two doses of MitoQ to placebo. MitoQ will be administered orally once daily. The primary endpoint of the study is the change in the levels of alanine aminotransferase , a liver enzyme in greater amounts in greater amounts when the liver is inflamed, at the end of the treatment period compared to baseline value. Mitochondrial protective agents and mitochondria-directed antioxidants represent a unique direction for the development of drug candidates that can modify the pathogenesis of chronic hepatitis C, said Dr. Ken Taylor, CEO of Antipodean. MitoQ is a promising compound in this and other areas. We believe that MitoQ could be used to stop or reduce liver inflammation and fibrosis progression, even in the absence of virologic be. ..
‘.. Antipodean Pharmaceuticals Initiates Phase 2 trial in hepatitis CAntipodean Pharmaceuticals, announced today that a Phase 2 clinical trial of lead compound MitoQ of the drug evaluate the efficacy of the drug to liver damage in patients with elevated reduce liver enzymes associated with the hepatitis C virus . The principal investigator for the study enrolled Dr. Edward Gane, Associate Professor of Medicine, New Zealand Liver Transplant Unit at Auckland City Hospital, the first patient.Past studies have depressions and Alzheimer’s disease are connected, according to background information on items. Man by a lifetime story of the major depressive disorder may be to be more diagnoses by AD. Moreover, affect of both AD and MDD probability of memory-related temporal lobes of brain. MDD is most likely caused atrophy hippocampal, of area where the most amount of plaques and fibrils forming in patients with AD, the authors write.